SUVEN LIFE SCIENCES: ROPSNICANT FOR MAJOR DEPRESSIVE DISORDER

Suven Life Sciences announced topline results from its Phase-2b clinical proof-of-concept trial of Ropanicant for Major Depressive Disorder (MDD). Ropanicant 45 mg twice daily treatment demonstrated clinically meaningful improvement in Montgomery-Åsberg Depression Rating Scale (MADRS), total score compared with placebo at Week 6. The maximum likelihood (ML) - estimated mean difference from baseline versus placebo is -3.572 in the Full Analysis Set (p = 0.038). Improvement in anhedonia correlated with improvements in measures of functioning and quality of life. No withdrawal symptoms or dissociation were observed after discontinuation of Ropanicant treatment. Global Phase-3 registrational study in MDD is being planned. The trial enrolled 214 patients and evaluated the efficacy and safety of Ropanicant 45 or 30 mg administered twice daily compared with placebo. Ropanicant is a novel, selective nicotinic a4ẞ2 receptor antagonist in development for MDD. Suven fully owns all the intellectual property rights of Ropanicant.

Suven Life Sciences Limited

Open attachment

← Back to feed